PH12016501529A1 - Internal liquid agent - Google Patents

Internal liquid agent

Info

Publication number
PH12016501529A1
PH12016501529A1 PH12016501529A PH12016501529A PH12016501529A1 PH 12016501529 A1 PH12016501529 A1 PH 12016501529A1 PH 12016501529 A PH12016501529 A PH 12016501529A PH 12016501529 A PH12016501529 A PH 12016501529A PH 12016501529 A1 PH12016501529 A1 PH 12016501529A1
Authority
PH
Philippines
Prior art keywords
liquid agent
internal liquid
suppressed
pigment
ambroxol
Prior art date
Application number
PH12016501529A
Other versions
PH12016501529B1 (en
Inventor
Masashi Yamamoto
Koji Mochizuki
Hitoshi Inokuchi
Shinichi Mita
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PH12016501529B1 publication Critical patent/PH12016501529B1/en
Publication of PH12016501529A1 publication Critical patent/PH12016501529A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An internal liquid agent containing ambroxol hydrochloride, a pigment, polyethylene glycol, and an optional gallic acid or a derivative thereof, such that change in color of the ambroxol hydhrochloride due to irradiation of light is suppressed, precipitate is not formed, discoloration of the pigment due to heat is suppressed, and bitterness of the ambroxol hydrochloride is suppressed.
PH12016501529A 2014-02-18 2016-08-03 Internal liquid agent PH12016501529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014028361 2014-02-18
PCT/JP2015/054207 WO2015125757A1 (en) 2014-02-18 2015-02-17 Internal liquid agent

Publications (2)

Publication Number Publication Date
PH12016501529B1 PH12016501529B1 (en) 2017-02-06
PH12016501529A1 true PH12016501529A1 (en) 2017-02-06

Family

ID=53878259

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501529A PH12016501529A1 (en) 2014-02-18 2016-08-03 Internal liquid agent

Country Status (3)

Country Link
JP (1) JP6372559B2 (en)
PH (1) PH12016501529A1 (en)
WO (1) WO2015125757A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3949184B2 (en) * 1995-06-13 2007-07-25 テイコクメディックス株式会社 Ambroxol hydrochloride aqueous solution
JP2000007561A (en) * 1998-06-18 2000-01-11 Nissho Corp Ambroxol hydrochloride aqueous solution preparation
US20050075403A1 (en) * 2003-10-02 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of inflammation in the pharynx
ITMI20032463A1 (en) * 2003-12-16 2005-06-17 Advance Holdings Ltd AQUEOUS CONCENTRATED AMBROXOL SOLUTION
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol

Also Published As

Publication number Publication date
PH12016501529B1 (en) 2017-02-06
JP6372559B2 (en) 2018-08-15
JPWO2015125757A1 (en) 2017-03-30
WO2015125757A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
EA201790649A1 (en) BENZE-SUBSTITUTED INDAZOLES AS BUB 1 INHIBITORS
CL2016002027A1 (en) Cyclopropylamine as an inhibitor of lsd1
PH12016501748A1 (en) Durable extruded dyed polyester films
CR20150571A (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
BR112016018555A8 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS, THEIR USE, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND LSD1 INHIBITION METHOD
CL2015002628A1 (en) Heteroaryl compounds and their uses.
BR112016014020A2 (en) GPR6 TETRAHYDROPYRIDOPYRAZINE MODULATING COMPOUNDS, THEIR SALTS AND THEIR USES
CL2014001793A1 (en) Compounds derived from substituted 1,3,5-triazines and their salts, as inhibitors of mutant idh2; pharmaceutical composition that includes them; and its use for the treatment of cancer.
BR112015021524A2 (en) sulfonyl quinoline derivatives and uses thereof
BR112016025396A2 (en) heterocyclyl butanamide derivatives
MA39495A (en) ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES
BR112017008481A2 (en) antimycotic compound
EP3408254A4 (en) Salts of 5-aminolevulinic acid and derivatives
CL2017001025A1 (en) Compounds for use in anthelmintic treatment
DOP2017000058A (en) TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMINUM INHIBITORS
MX2017007577A (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof.
AR104591A1 (en) VORTIOXETINE PYROGLUTAMATE
BR112016026470A2 (en) Hsp70 modulating compound, pharmaceutical composition comprising it and use of said compound
BR112015024703A2 (en) pharmaceutical formulation, method of treatment and / or prevention of restenosis and kit for the treatment and / or prevention of restenosis
MX2018003802A (en) Formulation of hypericin for photodynamic diagnosis.
PH12016501529A1 (en) Internal liquid agent
DOP2016000325A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
PH12016501528B1 (en) Internal liquid agent
BR102014007923A8 (en) polymeric nanostructured system and its use
DK3331506T3 (en) Pediatric Formulation Containing Gallic Acid